Sanjay Kulkarni

Sanjay Kulkarni

Auto-generated profile, based on publicly available information

Sanjay Kulkarni

Yale University School of Medicine, New Haven, Connecticut

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in Circulation
Verified
Journal Article
Closed access
PDF file
DJDan Jane-Wit
Dan Jane-Wit
TMThomas D. Manes
Thomas D. Manes
TYTai Yi
Tai Yi
LQLingfeng Qin
Lingfeng Qin
PCPamela Clark
Pamela Clark
JPJordan S. Pober
Jordan S. Pober
Background—: Cardiac allograft vasculopathy is the major cause of late allograft loss after heart transplantation. Cardiac allograft vasculopathy lesions contain alloreactive T cells that secrete interferon-γ, a vasculopathic cytokine, and occur more frequently in patients with donor-specific antibody. Pathological interactions between these immune effectors, representing cellular and humoral immunity, respectively, remain largely unexplored. Methods and Results—: We used human panel reactive antibody to form membrane attack complexes on allogeneic endothelial cells in vitro and in vivo. Rather than inducing cytolysis, membrane attack complexes upregulated inflammatory genes, enhancing the capacity of endothelial cells to recruit and activate allogeneic interferon-γ––producing CD4 + T cells in a manner dependent on the activation of noncanonical nuclear factor-κB signaling. Noncanonical nuclear factor-κB signaling was detected in situ within endothelial cells both in renal biopsies from transplantation patients with chronic antibody-mediated rejection and in panel-reactive antibody––treated human coronary artery xenografts in immunodeficient mice. On retransplantation into immunodeficient hosts engrafted with human T cells, panel-reactive antibody––treated grafts recruited more interferon-γ––producing T cells and enhanced cardiac allograft vasculopathy lesion formation. Conclusions—: Alloantibody and complement deposition on graft endothelial cells activates noncanonical nuclear factor-κB signaling, initiating a proinflammatory gene program that enhances alloreactive T cell activation and development of cardiac allograft vasculopathy. Noncanonical nuclear factor-κB signaling in endothelial cells, observed in human allograft specimens and implicated in lesion pathogenesis, may represent a target for new pharmacotherapies to halt the progression of cardiac allograft vasculopathy.

8 August 2016 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
SKS. Kulkarni
S. Kulkarni
NKN. C. Kirkiles‐Smith
N. C. Kirkiles‐Smith
YDY. H. Deng
Y. H. Deng
RFR N Formica
R N Formica
GMG. Moeckel
G. Moeckel
RFR. N. Formica
R. N. Formica
We hypothesized that de novo donor‐specific antibody (DSA) causes complement‐dependent endothelial cell injury in kidney transplants, as assessed by expression of endothelial cell–associated transcripts (ENDATs), that may be attenuated through complement inhibition. In total, 15 participants (five control, 10 treatment) with DSA and deteriorating renal function were enrolled. The treatment group received 6 mo of eculizumab followed by 6 mo of observation, whereas controls were observed. The primary end point was percentage change in estimated GFR (eGFR) trajectory over the treatment period. The treatment group had an improved eGFR trajectory versus control, based on our predetermined two‐sided 0.10 significance level (p = 0.09). Within‐subject analysis of treated participants at 6‐mo intervals did not show significant change (p = 0.60). Modeling C1q status showed that C1q‐positive patients had significantly higher mean eGFR than patients with negative C1q (p = 0.04). Biopsies revealed elevated renal ENDATs in most participants, but ENDATs were not reduced with complement inhibition. Our data suggest that eculizumab treatment may stabilize kidney function in patients with chronic persistent DSA based on our pilot a priori significance threshold. ENDAT expression predicative of acute humoral injury is not reduced with complement inhibition in this chronic setting. Further studies will be necessary to determine which patients may benefit from eculizumab.

1 April 2016 in American Journal of Kidney Diseases
Verified
Journal Article
Open access
PDF file
LRLionel Rostaing
Lionel Rostaing
SBSuphamai Bunnapradist
Suphamai Bunnapradist
KCKazimierz Ciechanowski
Kazimierz Ciechanowski
JDJason E. Denny
Jason E. Denny
HSHelio Tedesco Silva
Helio Tedesco Silva
RPRandhawa Parmjeet
Randhawa Parmjeet
1-year data from this trial showed the noninferiority of a novel once-daily extended-release tacrolimus (LCPT; Envarsus XR) to immediate-release tacrolimus (IR-Tac) twice daily after kidney transplantation. Final 24-month analysis of a 2-armed, parallel-group, randomized, double-blind, double-dummy, multicenter, phase 3 trial. 543 de novo kidney recipients randomly assigned to LCPT (n = 268) or IR-Tac (n = 275); 507 (93.4%) completed the 24-month study. LCPT tablets once daily at 0.17 mg/kg/d or IR-Tac twice daily at 0.1 mg/kg/d; subsequent doses were adjusted to maintain target trough ranges (first 30 days, 6-11 ng/mL; thereafter, 4-11 ng/mL). The intervention was 24 months; the study was double blinded for the entirety. Treatment failure (death, transplant failure, biopsy-proven acute rejection, or loss to follow up) within 24 months. Safety end points included adverse events, serious adverse events, new-onset diabetes, kidney function, opportunistic infections, and malignancies. Pharmacokinetic measures included total daily dose (TDD) of study drugs and tacrolimus trough levels. 24-month treatment failure was LCPT, 23.1%; IR-Tac, 27.3% (treatment difference, −4.14% [95% CI, −11.38% to +3.17%], well below the +10% noninferiority criterion defined for the primary 12-month end point). Subgroup analyses showed fewer treatment failures for LCPT versus IR-Tac among black, older, and female recipients. Safety was similar between groups. From month 1, TDD was lower for LCPT; the difference increased over time. At month 24, mean TDD for LCPT was 24% lower than for the IR-Tac group (P < 0.001), but troughs were similar (means at 24 months: LCPT, 5.47 ± 0.17 ng/mL; IR-Tac, 5.8 ± 0.30 ng/mL; P = 0.4). Trial participant eligibility criteria may limit the generalizability of results to the global population of de novo kidney transplant recipients. Results suggest that once-daily LCPT in de novo kidney transplantation has comparable efficacy and safety profile to that of IR-Tac. Lower TDD reflects LCPT’s improved bioavailability and absorption.

1 August 2010 in American Journal of Kidney Diseases
Verified
Journal Article
Open access
PDF file
MBMargaret Bia
Margaret Bia
DADeborah B. Adey
Deborah B. Adey
RBRoy D. Bloom
Roy D. Bloom
LCLaurence Chan
Laurence Chan
SKSanjay Kulkarni
Sanjay Kulkarni
STSteven Tomlanovich
Steven Tomlanovich
In response to recently published KDIGO (Kidney Disease: Improving Global Outcomes) guidelines for the care of kidney transplant recipients (KTRs), the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) organized a working group of transplant nephrologists and surgeons to review these guidelines and comment on their relevance and applicability for US KTRs. The following commentaries on the KDIGO guidelines represent the consensus of our work group. The KDIGO transplant guidelines concentrated on aspects of transplant care most important to this population in the posttransplant period, such as immunosuppression, infection, malignancy, and cardiovascular care. Our KDOQI work group concurred with many of the KDIGO recommendations except in some important areas related to immunosuppression, in which decisions in the United States are largely made by transplant centers and are dependent in part on the specific patient population served. Most, but not all, KDIGO guidelines are relevant to US patients. However, implementation of many may remain a major challenge because of issues of limitation in resources needed to assist in the tasks of educating, counseling, and implementing and maintaining lifestyle changes. Although very few of the guidelines are based on evidence that is strong enough to justify their being used as the basis of policy or performance measures, they offer an excellent road map to navigate the complex care of KTRs.

1 July 2019 in JAMA Surgery
Verified
Journal Article
Open access
PDF file
SKSanjay Kulkarni
Sanjay Kulkarni
KLKeren Ladin
Keren Ladin
DHDanielle Haakinson
Danielle Haakinson
EGErich Greene
Erich Greene
LLLuhang Li
Luhang Li
YDYanhong Deng
Yanhong Deng
Patients with end-stage renal disease, who are made inactive on the kidney transplant waiting list, have a higher mortality.1 There are several reasons an individual may be made inactive after listing for transplant including medical comorbidities, incomplete testing, psychosocial issues, or financial constraints.2-4 Patients work with their health care professionals, social workers, and transplant team to resolve these issues to attain active status, which confers the ability to obtain deceased donor organ offers. It is understandable that the ability to resolve the causes for inactivity may be more difficult for individuals with less access to health care, social support, or financial resources. Yet, to date, the implications and impact of a wait-list inactive status change on a patients’ future chances of obtaining a kidney transplant remain unknown.

26 August 2019 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
BSBernd Schröppel
Bernd Schröppel
EAEnver Akalin
Enver Akalin
MBMukta Baweja
Mukta Baweja
RBRoy D. Bloom
Roy D. Bloom
SFSander Florman
Sander Florman
PHPeter S. Heeger
Peter S. Heeger
Animal models and observational human data indicate that complement, including C5a, pathogenically participates in ischemia reperfusion (IR) injury that manifests as delayed graft function (DGF) following deceased donor kidney transplantation. We report on the safety/efficacy of anti‐C5 monoclonal antibody eculizumab (ECU) administered in the operating room prior to reperfusion, to prevent DGF in recipients of deceased donor kidney transplants in two related, investigator‐sponsored, randomized controlled trials. Eight recipients from a single center were enrolled in a pilot study that led to a 19 subject multicenter trial. Together, 27 deceased donor kidney transplant recipients, 16 ECU‐treated and 11 controls, were treated with rabbit anti‐thymocyte globulin, tacrolimus, mycophenolate mofetil with or without glucocorticoids, and followed for 6 months. Data analysis showed no epidemiological or transplant‐related differences between study arms. ECU was well tolerated with a similar severe adverse event incidence between groups. The DGF rate did not differ between ECU‐treated (44%) and control (45%, p=1.0) subjects. Serum creatinine reduction in the first week after transplantation, and graft function up to 180‐days post‐transplant, were also similar. ECU administration was safe but did not reduce the rate of DGF in a high‐risk population of deceased donor recipients.